Astria Therapeutics(ATXS) - 2024 Q3 - Quarterly Report

Financial Performance - The company reported net losses of $68.6 million for the nine months ended September 30, 2024, compared to$41.5 million for the same period in 2023[65]. - The company has an accumulated deficit of $649.2 million as of September 30, 2024, and has not generated any product revenues[65]. - Net loss for the nine months ended September 30, 2024, was$68.63 million, an increase of $27.15 million or 65$41.48 million in the prior year[74]. - Other income, net increased by $6.0 million to$13.3 million for the nine months ended September 30, 2024, a 82% increase from $7.3 million in the same period of 2023[77]. - For the nine months ended September 30, 2024, net cash used in operating activities was$63.9 million, compared to $38.2 million for the same period in 2023[83]. - Net cash used in investing activities was$188.1 million for the nine months ended September 30, 2024, primarily due to purchases of short-term investments totaling $3.5 billion[83]. - Net cash provided by financing activities was$157.2 million for the nine months ended September 30, 2024, driven by net proceeds from the February 2024 Financing and ATM Programs[85]. Cash and Funding - As of September 30, 2024, the company had $344.3 million in cash, cash equivalents, and short-term investments, expected to fund operations into mid-2027[65]. - The gross proceeds from the October 2023 Financing were$64.0 million, and from the February 2024 Financing were $125.0 million[64]. - Existing cash, cash equivalents, and short-term investments are expected to fund operations into mid-2027, covering ongoing clinical trials and development activities[86]. - The company expects to finance future cash needs through equity offerings, debt financings, and collaborations, with no committed external sources of funds[88]. - The company sold 1,504,619 shares under the 2024 ATM Program for gross proceeds of$15.6 million in the three months ended September 30, 2024[81]. Research and Development - Research and development expenses increased by $26.5 million to$56.9 million for the nine months ended September 30, 2024, representing an 87% increase compared to the same period in 2023[75]. - Research and development expenses for the three months ended September 30, 2024, were $20.5 million, a 54$13.3 million in the same period of 2023[72]. - The company expects to incur significant research and development expenses in 2024 related to clinical trials for navenibart and STAR-0310, with higher expenses anticipated over the next several quarters[72]. Clinical Trials and Product Development - Navenibart achieved a 92% reduction in monthly attack rate and a 96% reduction in moderate and severe attacks in Cohort 1 after 6 months of follow-up[57]. - In Cohort 2, a 600 mg dose followed by a 300 mg dose resulted in a 96% reduction in monthly attack rate and 67% of patients were attack-free after 6 months[59]. - The company plans to initiate a Phase 1a clinical trial for STAR-0310 in healthy subjects in Q1 2025, with initial results expected in Q3 2025[63]. - The company aims to start a Phase 3 pivotal trial for Navenibart in Q1 2025, with top-line results expected by year-end 2026[59]. - STAR-0310 exhibited a long mean half-life of 26 days in preclinical studies, compared to 10-14 days for typical non-half-life extended IgG antibodies[60]. - Navenibart has received Fast Track and Orphan Drug designations from the FDA for the treatment of hereditary angioedema[57]. Operating Expenses - General and administrative expenses rose by $6.6 million to$25.0 million for the nine months ended September 30, 2024, a 36% increase from the prior year[77]. - General and administrative expenses for the three months ended September 30, 2024, increased by $1.6 million to$8.5 million, a 23% increase from the prior year[72]. - Total operating expenses for the nine months ended September 30, 2024, were $81.97 million, up$33.14 million or 68% from $48.83 million in the same period of 2023[74]. - Total operating expenses for the three months ended September 30, 2024, were$29.01 million, up $8.78 million or 43$20.24 million in the same period of 2023[71]. Internal Controls - The company has not made any changes to its internal control over financial reporting that materially affected its financial reporting during the nine months ended September 30, 2024[92].